News from Karo Pharma

18 February, 2021

Year-end report 2020

Q4, October – December Net sales amounted to MSEK 721.2 (649.3). This corresponds to an increase of 11% for the period. The organic growth* during the fourth quarter was +1%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson...

3 February, 2021

Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals

Karo Pharma Aktiebolag (“Karo”) today announces the acquisition of an OTC brand portfolio containing Flux^®, Decubal^®, Lactocare^®, Apobase^®, Dailycare^® and Fludent^® from Teva Pharmaceuticals (Teva) for a total consideration of EUR 84m.